Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer

Translational Oncology

Volumn 7, Issue 5, 2014, Pages 613-619

  Supernat, Anna ^a   Łapińska Szumczyk, Sylwia ^b   Majewska, Hanna ^b   Gulczyński, Jacek ^b   Biernat, Wojciech ^b   Wydra, Dariusz ^b   Żaczek, Anna J ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA TOPOISOMERASE II ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN KINASE B; PROTEIN P53; RAD21 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CELL HETEROGENEITY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

EID: 84915794605     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.06.001     Document Type: Article

References (42)

1. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, and Group EGW (2011). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl. 6), vi35–vi39.
2. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, and Tarpey P, et al (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. NEngl JMed 366, 883–892.
3. Meacham CE and Morrison SJ (2013). Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, and Kinzler KW (2013). Cancer genome landscapes. Science 339, 1546–1558.
5. Mesko S, Kupelian P, Demanes DJ, Huang J, Wang PC, and Kamrava M (2013). Quantifying the ki-67 heterogeneity profile in prostate cancer. Prostate Cancer 2013, 1–5.
6. Pekar G, Gere M, Tarjan M, Hellberg D, and Tot T (2014). Molecular phenotype of the foci in multifocal invasive breast carcinomas: Intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy. Cancer 120, 26–34.
7. Pecorelli S (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105, 103–104.
8. Tavassoli FA and Devilee P (2003). WHO Classification of Tumours. Pathology and Genetics—Tumor of the Breast and Female Genital Organs. Lyon: World Health Organization.
9. WE Consultation (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163.
10. Altman DG, McShane LM, Sauerbrei W, and Taube SE (2012). Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9, e1001216.
11. Allred DC, Harvey JM, BerardoM, and Clark GM(1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11, 155–168.
12. Supernat A, Markiewicz A, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, Szade J, Czapiewski P, Biernat W, and Zaczek A (2012). CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol 20, 103–107.
13. Markiewicz A, Ahrends T, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Jaśkiewicz J, Szade J, Biernat W, and Zaczek AJ (2012). Expression of epithelial to mesenchymal transition-relatedmarkers in lymph nodemetastases as a surrogate for primary tumor metastatic potential in breast cancer. J TranslMed 10, 226.
14. Ljuslinder I, Malmer B, Isaksson-Mettävainio M, Oberg A, Henriksson R, Stenling R, and Palmqvist R (2009). ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 29, 1489–1494.
15. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, and Vadgama JV (2008). Clinical significance of Akt and HER2/neu overexpression in African- American and Latina women with breast cancer. Breast Cancer Res 10, R3.
16. Blancato J, Singh B, Liu A, Liao DJ, and Dickson RB (2004). Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 90, 1612–1619.
17. Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, and Brodowicz T, et al (2011). Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology 80, 269–277.
18. Young RJ, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K, and Solomon B (2011). Relationship between epidermal growth factor receptor status, p16INK4A, and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 20, 1230–1237.
19. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, and Teh M (2007). Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 109, 1097–1105.
20. Planagumà J, Díaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, García A, Baró T, Thomson TM, Xercavins J, and Alameda F, et al (2004). A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res 64, 8846–8853.
21. Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, and Denkert C (2012). Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7, e51862.
22. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, and Rabinovitch PS, et al (2006). Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38, 468–473.
23. Gerashchenko TS, Denisov EV, Litviakov NV, Zavyalova MV, Vtorushin SV, Tsyganov MM, Perelmuter VM, and Cherdyntseva NV (2013). Intratumor heterogeneity: nature and biological significance. Biochemistry (Mosc) 78, 1201–1215.
24. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, and Benz CC, et al (2013). Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73.
25. Fujii H, Marsh C, Cairns P, Sidransky D, and Gabrielson E (1996). Genetic divergence in the clonal evolution of breast cancer. Cancer Res 56, 1493–1497.
26. Heppner GH and Miller BE (1983). Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 2, 5–23.
27. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, and Cohen C (2010). Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol 18, 433–441.
28. Glöckner S, Buurman H, Kleeberger W, Lehmann U, and Kreipe H (2002). Marked intratumoral heterogeneity of c-myc and cyclin D1 but not of c-erbB2 amplification in breast cancer. Lab Invest 82, 1419–1426.
29. Patani N, Barbashina V, Lambros MB, Gauthier A, Mansour M, Mackay A, and Reis-Filho JS (2011). Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype. J Clin Pathol 64, 822–828.
30. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, and An SJ, et al (2012). EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 17, 978–985.
31. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, Dai D, Du W, Chen T, and Chen M (2012). Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 62, 221–228.
32. Buza N, English DP, Santin AD, and Hui P (2013). Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26, 1605–1612.
33. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, and Sinicrope FA (2012). Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 30, 3932–3938.
34. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, and Downing JR (2008). Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380.
35. Idoate M, Echeveste J, Diez Valle R, Lozano M, and Aristu J (2014). Biological and clinical significance of the intratumor heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of the PTEN gene in glioblastomas. Neuropathol Appl Neurobiol. http://dx.doi.org/10.1111/nan.12117 [Epub ahead of print].
36. Lesniewicz T, Kanczuga-Koda L, Baltaziak M, Jarzabek K, Rutkowski R, Koda M, Wincewicz A, Sulkowska M, and Sulkowski S (2009). Comparative evaluation of estrogen and progesterone receptor expression with connexins 26 and 43 in endometrial cancer. Int J Gynecol Cancer 19, 1253–1257.
37. Nijkamp MM, Hoogsteen IJ, Span PN, Takes RP, Lok J, Rijken PF, van der Kogel AJ, Bussink J, and Kaanders JH (2011). Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiother Oncol 101, 165–170.
38. Tabata K, Tanaka T, Hayashi T, Hori T, Nunomura S, Yonezawa S, and Fukuoka J (2014). Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered. BMC Clin Pathol 14, 23.
39. Buza N and Hui P (2013). Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes Cancer 52, 1178–1186.
40. Zhang XC, Xu C, Mitchell RM, Zhang B, Zhao D, Li Y, Huang X, Fan W, Wang H, and Lerma LA, et al (2013). Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing. Neoplasia 15, 1371–1378.
41. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, Di Narzo AF, Yan P, Hodgson JG, and Weinrich S, et al (2013). Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 231, 63–76.
42. http://www.proteinatlas.org/.